Navigation Links
Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
Date:5/21/2012

ROCKVILLE, Md., May 21, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, CEO and President, will present at the World Stem Cells & Regenerative Medicine Congress in London (http://www.terrapinn.com/2012/stemcells/index.stm) on Tuesday, May 22nd at 12:30 PM. Mr. Garr's presentation, "Stem Cell Applications for Neurodegenerative Disorders," will review Neuralstem's cellular therapy trial in ALS, its neurogenic small molecule trial in major depressive disorder (MDD), and provide an overview on plans to expand the cellular therapy program.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversin
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
2. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
5. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
6. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
7. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
8. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
9. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
10. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
11. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... with Capital Data, Inc. , an independent ... according to TeraMEDICA's executive vice president, Paul Schmelzer. ... TeraMEDICA's TI2m archive solution into its own enterprise ... includes Wisconsin, Minnesota, North Dakota, South Dakota, Iowa, ...
... organization? Any temper tantrums lately? Or an adolescent episode ... maybe just a bit of flagging memory? , ,Given ... time or another, it's easy to begin thinking about ... always wisdomas they age. It's even understandable to want ...
... Watts Wacker, hippie extraordinaire and rock-star futurist, spoke at ... week. I was floored by his insights and had ... Watts offered, along with some R-squared commentary: , ,Watts: ... Paulone of JC's disciplesfinally laid down, there were 200,000 ...
Cached Biology Technology:TeraMEDICA and Capital Data enter into diagnostic imaging agreement 2Aging IT 2Aging IT 3Watts Up 2
(Date:10/16/2014)... at William and Mary,s Virginia Institute of Marine ... the Environmental Protection Agency to identify the streams ... to develop tools to help local governments and ... depends critically on a dataset of tidal-marsh observations ... Only with this historical baseline can today,s researchers ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... brain develops, neurons reach out helter-skelter forming new connections, ... the brain chooses which connections to keep and which ... branches have the most electrical activity—a finding that could ... , The work, published in the April 21 issue ...
... specialized subpopulation of the antibody-producing B cells of the ... kinds of immunity -- innate and acquired, Duke University ... between B-1a and B-1b cells they have uncovered offers ... of vaccines, they said. , B cells are the ...
x...
Cached Biology News:Speak up: Louder neurons form more connections 2Specialized immune-system B cells play double-barreled role 2Specialized immune-system B cells play double-barreled role 3